34 completed, 4 recruiting, 4 terminated, 3 active not recruiting. 50 Phase 2, 6 Phase 3, 5 Phase 1.
Follow Eosinophilic Esophagitis: new trials by email Literature Review of Eosinophilic Esophagitis trials Research Report on Eosinophilic Esophagitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis Upadacitinib 30mg Dose, Upadacitinib Matching Placebo - EoE, Eosinophilic Esophagitis | Phase 2 | Recruiting | University of North Carolina, Chapel Hill | 52 | 2026-09-30 | 2026-10-06 |
| A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks Vonoprazan, Placebo - Eosinophilic Esophagitis | Phase 2 | Active not recruiting | Phathom Pharmaceuticals, Inc. | 95 | 2025-10-30 | 2026-10-13 |
| Zemaira Eosinophilic Esophagitis Pilot Study Alpha-proteinase inhibitor - Eosinophilic Esophagitis | Phase 2 | Recruiting | Children's Hospital Medical Center, Cincinnati | 15 | 2025-05-15 | 2025-12-17 |
| Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE Dupilumab, Fluticasone - Eosinophilic Esophagitis | Phase 2 | Recruiting | University of Colorado, Denver | 72 | 2024-12-23 | 2025-03-14 |
| A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis Solrikitug Low Dose, Solrikitug Mid Dose, Solrikitug High Dose - Eosinophilic Esophagitis (EoE) | Phase 2 | Active not recruiting | Uniquity One (UNI) | 184 | 2024-10-16 | 2026-03-20 |
| A Study of CDX-0159 in Patients With Eosinophilic Esophagitis barzolvolimab, Matching Placebo - Eosinophilic Esophagitis | Phase 2 | Completed | Celldex Therapeutics | 86 | 2023-06-01 | 2026-05-27 |
| A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have Dupilumab - Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD) | Phase 2 | Active not recruiting | Regeneron Pharmaceuticals | 22 | 2023-05-03 | 2026-07-01 |
| A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE). EP-104GI, Matching vehicle control - Eosinophilic Esophagitis | Phase 1 / Phase 2 | Recruiting | Eupraxia Pharmaceuticals Inc. | 117 | 2023-03-31 | 2026-03-19 |
| Mesalazine Oral Suspension in Active Eosinophilic Esophagitis Mesalamine Oral Product - Eosinophilic Esophagitis | Phase 2 | Completed | Dr. Falk Pharma GmbH | 5 | 2023-02-09 | 2023-09-07 |
| A Study to Investigate Safety and Tolerability of NDX-3315 and NDX-3324 in Healthy Participants and Patients With Eosinophilic Esophagitis NDX-3315, NDX-3324, SPECT/CT Imaging - Eosinophilic Esophagitis | Phase 2 | Completed | NexEos Diagnostics, Inc. | 34 | 2023-01-20 | 2026-05-14 |
| Targeted Elimination Diet in EoE Patients Following Identification of Trigger Nutrients Using Confocal Laser Endomicroscopy personalized exclusion diet based on CLE, empiric exclusion diet - Eosinophilic Esophagitis | Phase 1 / Phase 2 | Unknown | Universitaire Ziekenhuizen KU Leuven | 25 | 2022-02-16 | 2024-06-27 |
| A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis IRL201104, Placebo - Eosinophilic Esophagitis | Phase 2 | Completed | Revolo Biotherapeutics | 36 | 2021-10-29 | 2025-05-21 |
| A Study to Investigate the Efficacy and Tolerability of ESO-101 in Patients With Eosinophilic Esophagitis ESO-101, Placebo - Eosinophilic Esophagitis | Phase 2 | Completed | EsoCap AG | 43 | 2021-06-29 | 2023-11-14 |
| Pharmacokinetics, Efficacy, Tolerability and Safety of Different Budesonide Oral Gel Doses in Adults' Subjects of Both Genders With Eosinophilic Esophagitis (EoE) Budesonide Gel - Eosinophilic Esophagitis | Phase 2 | Withdrawn | Bazell Pharma AG | 2021-04-23 | 2024-08-23 | |
| Efficacy and Safety of Three Doses of Florence Oral Suspension in Adults With Eosinophilic Esophagitis Florence 30 μg/mL, Florence 60 μg/mL, Florence 90 μg/mL - Eosinophilic Esophagitis | Phase 2 | Unknown | EMS | 116 | 2021-04-19 | 2023-02-24 |
| A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic Esophagitis Etrasimod, Placebo - Eosinophilic Esophagitis | Phase 2 | Completed | Pfizer | 108 | 2020-12-15 | 2024-05-06 |
| Antihistamines in Eosinophilic Esophagitis Famotidine, Loratadine, Placebo - Eosinophilic Esophagitis | Phase 2 | Terminated | Mayo Clinic | 1 | 2020-07-10 | 2022-12-20 |
| A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis Placebo, lirentelimab (AK002) - Eosinophilic Esophagitis | Phase 2 / Phase 3 | Completed | Allakos Inc. | 277 | 2020-07-06 | 2024-01-02 |
| Mepo for Eosinophilic Esophagitis (EoE) Study Mepolizumab 300 mg, Mepolizumab 100 mg, Placebo - EoE, Eosinophilic Esophagitis | Phase 2 | Completed | University of North Carolina, Chapel Hill | 66 | 2019-03-20 | 2023-08-23 |
| An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis AK002 - Eosinophilic Gastritis, Eosinophilic Gastroenteritis | Phase 2 | Completed | Allakos Inc. | 58 | 2018-11-14 | 2024-02-28 |
Showing 20 of 50. Sign in to see all of them.
Esophagitis (10) · Deglutition Disorders (4) · Eosinophilic enteropathy (4) · Gastroesophageal Reflux (4) · Esophageal Diseases (3) · Digestive System Diseases (2) · Churg-Strauss Syndrome (1) · Connective Tissue Diseases (1) · Disease (1) · Eosinophilia (1) · Food Hypersensitivity (1) · Gastrointestinal Diseases (1) · Hematologic Diseases (1) · Hypereosinophilic Syndrome (1)
Gastroenteritis (50) · Hemic and Lymphatic Diseases (50) · Hypersensitivity, Immediate (50) · Immune System Diseases (50) · Eosinophilia (49) · Gastrointestinal Diseases (49) · Hematologic Diseases (49) · Hypersensitivity (49) · Leukocyte Disorders (49) · Digestive System Diseases (48) · Esophageal Diseases (47) · Esophagitis (40) · Esophageal Motility Disorders (4) · Otorhinolaryngologic Diseases (4) · Pharyngeal Diseases (4)
Budesonide (6) · Fluticasone (6) · AK002 (3) · Sodium Chloride (3) · dupilumab (3) · Esomeprazole (2) · Losartan (2) · Mometasone Furoate (2) · mepolizumab (2) · (5-fluoro-2-methyl-3-quinolin-2-ylmethylindo-1-yl)acetic acid (1) · 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine (1) · APT-1011 (1) · Angiotensin Receptor Antagonists (1) · BID protein, human (1) · Bethanechol (1)
Children's Hospital Medical Center, Cincinnati (6) · Mayo Clinic (4) · Allakos Inc. (3) · Dr. Falk Pharma GmbH (2) · Regeneron Pharmaceuticals (2) · Shire (2) · Swiss EE Study Group (2) · University of North Carolina, Chapel Hill (2) · University of Utah (2) · Adare Pharmaceuticals, Inc. (1) · Baylor College of Medicine (1) · Bazell Pharma AG (1) · Celgene (1) · Celldex Therapeutics (1) · Ception Therapeutics (1)
United States (38) · Switzerland (10) · Canada (7) · Australia (5) · Germany (5) · Netherlands (5) · Spain (5) · Belgium (4) · Italy (3) · Poland (3) · United Kingdom (3) · Brazil (1) · Japan (1) · New Zealand (1) · Sweden (1)
Marc E Rothenberg, MD, PhD (3) · Craig Paterson, MD (2) · Evan S Dellon, MD, MPH (2) · John C. Fang, M.D. (2) · Alex Straumann, Dr (1) · Alex Straumann, MD (1) · Amy D Klion, M.D. (1) · Amy Foxx-Orenstein, D.O. (1) · Andrew W Lee, MD (1) · Antonella Cianferoni, MD, PhD (1) · Carla M. Davis, MD (1) · Christoph Beglinger, MD (1) · Dawn Francis, MD (1)
PMID 20457157, PMID 22111863, PMID 22206777, PMID 24768678, PMID 24907494, PMID 24907502, PMID 25226850, PMID 25792708, PMID 27889574, PMID 29902649, PMID 30395812, PMID 30476587, PMID 30502508, PMID 31100455, PMID 31593702, PMID 32205221, PMID 32272243, PMID 33085861, PMID 33831327, PMID 34037993, PMID 34089846, PMID 35181572, PMID 35283330, PMID 35636689, PMID 35666852, PMID 36863390, PMID 37423717, PMID 37718471, PMID 37753954, PMID 38423296, PMID 39575597, PMID 39676687, PMID 40120806, PMID 40381637, PMID 41067281, PMID 41711386, PMID 42031097
U54AI117804 (2), 2009 (1), 2016 (1), R01DK135692 (1), R01DK146043 (1)